BUSINESS INSIGHTS

Adare Pharma Solutions Acquires Frontida BioPharm to Expand Leading CDMO Offerings

Adare Pharma Solutions | December 02, 2021

Adare Pharma Solutions Acquires Frontida BioPharm to Expand Leading CDMO Offerings
Adare Pharma Solutions ("Adare"), a technology-driven contract development and manufacturing organization (CDMO), announced the acquisition of Frontida BioPharm ("Frontida"), a vertically integrated CDMO focused on oral formulations. The acquisition reinforces Adare's commitment to transform drug delivery by providing world class solutions from product development through commercial scale manufacturing and packaging.  Adare's portfolio of offerings for its customers will expand to include new capabilities such as high potency compound handling and packaging services.  The combination of the two organizations will further establish Adare as a leader in the development and manufacturing of life saving medications in complex dosage forms.

 "We are devoted to improving the quality of life for patients by solving the most complex formulation challenges for our customers, and we believe this acquisition will bolster our ability to achieve our mission. Frontida and Adare share a commitment to quality and innovation, and we are excited to continue growing together.  The combined company will lead in the space of oral formulations, while expanding the services and technical offerings we provide to meet the needs of our customers and their patients."

Vivek Sharma, Chief Executive Officer of Adare 

Dr. Song Li, Frontida's Chairman added, "We are very excited about the opportunities this transaction is expected to provide to both existing and new clients. Our combined resources and capabilities will result in enhanced support and talent to ensure the success of their development and commercialization programs. This transaction is also a testament to the hard work, dedication, and caring culture of the team who has helped Frontida grow, enabling continued investment into the Philadelphia area, which is a respected home for pharmaceutical development and manufacturing. We look forward to continuing our work together to provide innovative, life-enhancing products to the US and global markets."

Together, the combined company will offer an expanded suite of solutions for complex oral formulations, such as taste masking, controlled release, high potency formulation manufacturing, and bioavailability enhancement. The addition of Frontida brings Adare's manufacturing footprint to seven sites globally and expands Adare's integrated, end-to-end offering to its partners. The combined organization will be led by Vivek Sharma.

Adare is backed by private equity firms Thomas H. Lee Partners and Frazier Healthcare Partners. RBC Capital Markets, LLC acted as exclusive financial advisor to Adare for this transaction.

About Adare
Adare Pharma Solutions is a leading specialty contract development and manufacturing organization (CDMO) and global provider of advanced pharmaceutical technologies, development services, and manufacturing. The Company utilizes its differentiated pharmaceutical technology and microbiome platforms to develop novel, improved medicines, and therapies for the global market.


Spotlight

According to UPI.com, "A new immune-boosting spray could stop recurrence of cancer in patients. The study, published Monday in the journal Nature Nanotechnology, detailed how researchers sprayed the surgical sites of mice with advanced melanoma tumors with calcium carbonate. The gel decreased the growth of the tumor cells following surgery.

Related News

PHARMA TECH

Veeva Development Cloud Simplifies Drug Development in the Industry

Veeva Systems | May 21, 2021

A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems in an industrywide shift to streamline drug development. quite 650 companies use Veeva Development Cloud applications today, and quite 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams. Veeva Development Cloud brings together suites of unified applications for clinical, regulatory, quality, and safety on one cloud platform, eliminating organizational siloes. quite 350 companies are accelerating trial execution with Vault Clinical applications, quite 250 are streamlining regulatory processes with Vault RIM, quite 350 are unifying quality management with Vault Quality, and quite 35 are improving pharmacovigilance with Vault Safety. Vault Connections in Veeva Development Cloud drive cross-functional business processes across the merchandise lifecycle. For instance, Connections enable companies to compile clinical operations and regulatory for faster submissions; quality and regulatory for simplified change control and variation management; and clinical data and operations for real-time visibility into patient enrollment. "We're dedicated to bringing innovations to plug that help the industry accelerate drug development," said Jim Reilly, vice chairman of Veeva Vault R&D. "Veeva Development Cloud is enabling customers to enhance collaboration across teams and speed the delivery of treatments to patients." About Veeva Systems Veeva is that the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves quite 975 customers, starting from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and therefore the industries it serves.

Read More

Vifor Pharma and Cara Therapeutics announces sign license agreement for IV Korsuva™* to treat dialysis patients with pruritus

Vifor Pharma and Cara Therapeutics, Inc. | October 20, 2020

Vifor Pharma and Cara Therapeutics, Inc. today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injection (“IV Korsuva”) for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement. “With an established fully dedicated nephrology sales force in the US, Vifor Pharma is an ideal commercialization partner to bring IV Korsuva to dialysis patients across the country,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “In addition, we believe Vifor Pharma’s existing relationships with US dialysis providers will provide significant momentum for the launch and adoption of IV Korsuva, if approved. As a result of this agreement, we expect to focus Cara’s internal resources on our clinical programs for Oral Korsuva in atopic dermatitis, pre-dialysis CKD and additional pruritic conditions.”

Read More

PHARMACY MARKET

TrialCard Launches Engage HCP

TrialCard | August 31, 2021

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement services for the following disciplines: Clinical Nurse Educators Field Reimbursement Managers Pharmaceutical Institutional, Sales, and Specialty Representatives Rare Disease Professionals Telepromotion Agents Medical Science Liaisons These augmented services strengthen TrialCard's original position in virtual detailing, which began several years ago. "TrialCard developed this suite of services to address for our clients the increasing number of "difficult to see" and "no see" HCPs," said Tom Heck, SVP of Commercial Solutions at TrialCard. "Engage HCP by TrialCard further solidifies our commitment to helping brands grow and thrive via non-traditional methods." Long before the COVID-19 global pandemic altered the traditional pharmaceutical selling cycle, pharma sales reps' access to HCPs had been decreasing for years. According to ZS's 2019 AffinityMonitor findings, only 47.3% of physicians engaged well with in-person pharma rep meetings, while just 9.6% of physicians engaged using digital tactics. TrialCard, a pioneer in digital HCP engagement, recognized this opportunity and began reaching out to physicians via digital channels years ago. "Many predict that it is unlikely society will ever return to pre-COVID-19 behavior," said Mark Bouck, President and CEO of TrialCard. "As HCPs become more accustomed and comfortable with digital communications, they will likely continue to become even less reliant on face-to-face interaction." "Our pharmaceutical sales reps enter the physician's office using technology instead of the front door," said Mike Davis, TrialCard's VP of Commercial Solutions. "While that technology is the backbone of our programs, our proven track record in supplementing a brand's field sales force is a result of the caliber of talent that we hire, the superior training and resources we provide, and the flexibility, experience, and expertise to create customized solutions for each client." About TrialCard TrialCard Incorporated is a full-service life sciences commercialization partner that provides comprehensive solutions that span the entire biopharmaceutical value chain. In addition to a foundation of fully integrated, digitally enabled patient support services, its broader offerings include everything from late-stage clinical trial management to post-marketing HCP engagement services and proprietary data-as-a-service payer intelligence and insights. Founded in 2000, TrialCard provides commercialization needs for more than 160 life science customers and has connected over 35 million patients with more than $18 billion in branded drug savings to date. The company is headquartered in Morrisville, North Carolina.

Read More

Spotlight

According to UPI.com, "A new immune-boosting spray could stop recurrence of cancer in patients. The study, published Monday in the journal Nature Nanotechnology, detailed how researchers sprayed the surgical sites of mice with advanced melanoma tumors with calcium carbonate. The gel decreased the growth of the tumor cells following surgery.